Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022

H Harriet Rumgay (Cancer Surveillance Branch International Agency for Research on Cancer Lyon France) M Murielle Colombet (Cancer Surveillance Branch International Agency for Research on Cancer Lyon France) A Amanda Ramos da Cunha (Cancer Surveillance Branch International Agency for Research on Cancer Lyon France) A Adalberto M. Filho (Cancer Surveillance Branch International Agency for Research on Cancer Lyon France) S Saman Warnakulasuriya (King’s College London London UK) D David I. Conway (School of Medicine, Dentistry, and Nursing University of Glasgow Glasgow UK) A Anil Chaturvedi (Division of Cancer Epidemiology and Genetics National Cancer Institute Rockville Maryland USA) S Shama Virani (Genetic Epidemiology Branch International Agency for Research on Cancer Lyon France) B Beatrice Lauby‐Secretan (Evidence Synthesis and Classification Branch International Agency for Research on Cancer Lyon France) A Andre L. Carvalho (Early Detection, Prevention, and Infections Branch International Agency for Research on Cancer Lyon France) S Suzanne T. Nethan (Evidence Synthesis and Classification Branch International Agency for Research on Cancer Lyon France) A Ahmedin Jemal (Surveillance and Health Equity Science American Cancer Society Atlanta Georgia USA) F Freddie Bray (Cancer Surveillance Branch International Agency for Research on Cancer Lyon France)

Abstract

ABSTRACT Cancers of the lip, oral cavity, and pharynx (LOCP) represent a substantial public health challenge worldwide. Using GLOBOCAN national estimates of incidence, detailed cancer registry data from Cancer Incidence in Five Continents , and population statistics from the United Nations, the authors report the distribution of new cases of LOCP cancers in 185 countries by sex in 2022. Age‐standardized incidence rates were calculated. For countries lacking registry data, regional averages from high‐quality registries were used to impute subsite‐specific estimates. Worldwide, 758,000 people were diagnosed with LOCP cancers in 2022, with oral cavity cancer accounting for approximately 42% of cases, followed by oropharynx (19.3%), nasopharynx (15.9%), hypopharynx (11.4%), salivary gland (7.3%), and lip (4.2%) cancers. Oral cavity cancer was the most frequent LOCP subsite among women in 141 countries and among men in 93 countries, and incidence rates were highest in countries in South‐Central Asia. Oropharyngeal cancer was the most frequent LOCP subsite among men in 44 countries and among women in five countries across Europe, Northern America, South America, Australia, and New Zealand. Nasopharyngeal cancer was the most common subsite among men in 39 countries and women in 23 countries, mainly in Northern Africa, Middle Africa, and Eastern and South‐Eastern Asia. Rates of hypopharyngeal and salivary gland cancers were low globally, although the incidence burden was greater than that of lip cancer. The authors discuss incidence patterns in relation to disease etiology and the prospects of delivering effective cancer control measures, spanning primary prevention, early detection, cancer treatment, and survivorship.

Article Details

Volume / Issue Vol. 76, Issue 1
Published January 01, 2026
ISSN 0007-9235
Publisher Wiley

Journal Info

CA: A Cancer Journal for Clinicians

Wiley

ISSN: 0007-9235 Open Access Q1 Medicine

Authors (13)

H

Harriet Rumgay

Cancer Surveillance Branch International Agency for Research on Cancer Lyon France

M

Murielle Colombet

Cancer Surveillance Branch International Agency for Research on Cancer Lyon France

A

Amanda Ramos da Cunha

Cancer Surveillance Branch International Agency for Research on Cancer Lyon France

A

Adalberto M. Filho

Cancer Surveillance Branch International Agency for Research on Cancer Lyon France

S

Saman Warnakulasuriya

King’s College London London UK

D

David I. Conway

School of Medicine, Dentistry, and Nursing University of Glasgow Glasgow UK

A

Anil Chaturvedi

Division of Cancer Epidemiology and Genetics National Cancer Institute Rockville Maryland USA

S

Shama Virani

Genetic Epidemiology Branch International Agency for Research on Cancer Lyon France

B

Beatrice Lauby‐Secretan

Evidence Synthesis and Classification Branch International Agency for Research on Cancer Lyon France

A

Andre L. Carvalho

Early Detection, Prevention, and Infections Branch International Agency for Research on Cancer Lyon France

S

Suzanne T. Nethan

Evidence Synthesis and Classification Branch International Agency for Research on Cancer Lyon France

A

Ahmedin Jemal

Surveillance and Health Equity Science American Cancer Society Atlanta Georgia USA

F

Freddie Bray

Cancer Surveillance Branch International Agency for Research on Cancer Lyon France